Location
Moultrie, GA
Start Date
7-5-2025 1:00 PM
End Date
7-5-2025 4:00 PM
Description
Chronic pelvic pain (CPP) is a complex syndrome often associated with a variety of somatic, psychological, and functional impairments. This case report describes a 45-year-old woman with a history of CPP secondary to a traumatic delivery, who presented with persistent vaginal and perineal pain unresponsive to prior conservative therapies, including gabapentin and physical therapy. Following initiation of a multimodal treatment regimen incorporating a compounded topical cream containing 2% amitriptyline (AMI) and 0.5% ketamine (KET), the patient reported substantial improvement in pain, functionality, and quality of life. While the cream was well tolerated initially, prolonged use led to adverse effects, including vivid dreams and nocturnal orgasmic contractions, necessitating reduced frequency of application. Despite this, the patient experienced continued significant pain relief and was able to resume daily activities with minimal impact on her quality of life. This case highlights the potential utility of compounded topical AMI-KET cream as part of a multimodal treatment approach for CPP, particularly in patients who are unsuitable for or unwilling to undergo interventional procedures. Further research is warranted to better define the role of topical AMI-KET cream in the management of CPP.
Embargo Period
6-3-2025
Included in
Case Report: The Treatment of Chronic Pelvic Pain Utilizing Topical Amitriptyline-Ketamine Compound Cream
Moultrie, GA
Chronic pelvic pain (CPP) is a complex syndrome often associated with a variety of somatic, psychological, and functional impairments. This case report describes a 45-year-old woman with a history of CPP secondary to a traumatic delivery, who presented with persistent vaginal and perineal pain unresponsive to prior conservative therapies, including gabapentin and physical therapy. Following initiation of a multimodal treatment regimen incorporating a compounded topical cream containing 2% amitriptyline (AMI) and 0.5% ketamine (KET), the patient reported substantial improvement in pain, functionality, and quality of life. While the cream was well tolerated initially, prolonged use led to adverse effects, including vivid dreams and nocturnal orgasmic contractions, necessitating reduced frequency of application. Despite this, the patient experienced continued significant pain relief and was able to resume daily activities with minimal impact on her quality of life. This case highlights the potential utility of compounded topical AMI-KET cream as part of a multimodal treatment approach for CPP, particularly in patients who are unsuitable for or unwilling to undergo interventional procedures. Further research is warranted to better define the role of topical AMI-KET cream in the management of CPP.